Allogene Therapeutics (ALLO)
(Delayed Data from NSDQ)
$2.98 USD
+0.02 (0.68%)
Updated May 15, 2024 04:00 PM ET
After-Market: $2.98 0.00 (0.00%) 6:06 PM ET
2-Buy of 5 2
F Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Allogene Therapeutics, Inc. [ALLO]
Reports for Purchase
Showing records 201 - 213 ( 213 total )
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q19 - Allogene Continues to Aim for Excellence in ALLO CAR-T Delivery
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Rafael Amado Joins Allogene as Chief Medical Officer
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Cell Therapy 2.0: Moving Beyond CAR-Ts in Immuno-Oncology
Provider: Roth Capital Partners, Inc.
Company: Allogene Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Round 2 May Supersede Round 1 and It''s Priced In. Initiating at Neutral.
Provider: Roth Capital Partners, Inc.